Testing for Rupture of Membranes: Reviewing the Accuracy of Point-of-Care Tests
- Hannah Hunt
- May 8
- 3 min read
Accurate diagnosis of rupture of membranes (PROM) is essential for supporting timely clinical decision-making and ensuring appropriate patient management. However, false positive results remain a significant challenge in practice, potentially leading to unnecessary interventions, increased healthcare costs, avoidable admissions, and additional anxiety for patients.
As maternity services continue to focus on efficiency, evidence-based care, and reducing unnecessary resource utilisation, the accuracy of point-of-care PROM testing has become increasingly important.
The Clinical and Economic Impact of False Positives
A positive PROM diagnosis can trigger a cascade of clinical interventions. An economic evaluation published by YHEC highlighted the potential financial implications associated with a false positive PROM diagnosis and the importance of reliable testing pathways.1
Why Diagnostic Accuracy Matters
When assessing point-of-care PROM tests, both sensitivity and specificity are critical.
High sensitivity helps ensure true cases of membrane rupture are correctly identified.
High specificity helps minimise false positives and unnecessary intervention.
Achieving both is essential for confident bedside diagnosis and effective clinical management.
Why AmniSure® Stands Out
AmniSure® has been extensively studied and has demonstrated strong diagnostic performance across multiple peer-reviewed studies, particularly when compared with IGFBP-1-based assays.2–5
The test detects placental alpha microglobulin-1 (PAMG-1), a protein present in very high concentrations in amniotic fluid and minimal levels in other bodily fluids. This specificity contributes to the test’s high accuracy and low false positive rate.
Multiple studies have reported 6,7:
98.9% sensitivity
98–100% specificity
99% correlation with the gold standard indigo carmine injection test
According to published European guidelines, PAMG-1-based testing was considered the most accurate bedside diagnostic method for PROM compared with alternative testing approaches. 8
Supporting Better Clinical Decision-Making
Reliable true positive results help clinicians make faster and more informed decisions regarding patient management. Greater diagnostic confidence can support:
Appropriate and timely intervention
Reduced avoidable admissions
More targeted antibiotic use
Improved patient reassurance and experience
For busy maternity units, dependable bedside testing also helps streamline workflows and reduce unnecessary repeat assessments.
Designed for Point-of-Care Use
AmniSure® is designed to integrate easily into routine clinical practice.
Key practical advantages include:
Highest reported accuracy of any point-of-care ROM test
98.9% sensitivity and 100% specificity 6
No speculum required
Suitable across all gestational ages
Resistant to interference from common contaminants
Rapid bedside result in 10 minutes
Supported by major clinical guidelines
The test is also referenced in NICE, RCOG, and European clinical guidelines.
Conclusion
As maternity services seek to balance clinical accuracy with efficient resource management, reliable PROM testing remains a critical component of patient care.
With strong evidence supporting its diagnostic performance, AmniSure® provides clinicians with a highly accurate point-of-care option that may help reduce false positives, support appropriate intervention, and improve patient experience.
References
Economic Evaluation Case Study: AmniSure. YHEC 2020
Chen F, Dudenhausen J. Comparison of Two Rapid Strip Tests Based on IGFBP-1 and PAMG-1 for the Detection of Amniotic Fluid. Am J Perinatol. 2008;25:243–246.
Gaucherand P, Doret M, et al. Detection of Placental Alpha Microglobulin-1 versus Insulin-Like Growth Factor-Binding Protein-1 in Amniotic Fluid at Term: A Comparative Study. Am J Perinatol. 2011;6:489–494.
Tagore S, Kwek K. Comparative analysis of insulin-like growth factor binding protein-1 (IGFBP-1), placental alpha microglobulin-1 (PAMG-1) and nitrazine test to diagnose premature rupture of membranes in pregnancy. Am J Perinatol. 2008;25:243–246.
Albayrak M, Ozdemir I, Koc O, Ankarali H, Oren O. Comparison of the diagnostic efficacy of the two rapid bedside immunoassays and combined clinical conventional diagnosis in prelabour rupture of membranes. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):179–182.
Cousins LM et al. AmniSure Placental Alpha Microglobulin-1 Rapid Immunoassay versus Standard Diagnostic Methods for Detection of Rupture of Membranes. Am J Perinatol. 2005;22:317–320.
Sosa CG et al. Comparison of placental alpha microglobulin-1 in vaginal fluid with intra-amniotic injection of indigo carmine for the diagnosis of rupture of membranes. J Perinat Med. 2014;42(5):611–616.
Di Renzo GC, Cabero Roura L, Facchinetti F et al. Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Maternal-Fetal Neonatal Med. 2011;24(5):659–667.
